1 Guidance

1 Guidance

1.1 Alemtuzumab is recommended as an option, within its marketing authorisation, for treating highly active relapsing–remitting multiple sclerosis in adults with:

  • highly active disease despite a full and adequate course of treatment with at least 1 disease-modifying therapy or

  • rapidly-evolving severe relapsing-remitting multiple sclerosis defined by 2 or more disabling relapses in 1 year, and with 1 or more gadolinium-enhancing lesions on brain MRI or a significant increase in T2 lesion load compared with a previous MRI.

  • National Institute for Health and Care Excellence (NICE)